WO2006038527A1 - Antitumor immunostimulant containing extract from pleurotus cornucopiae as active ingredient - Google Patents

Antitumor immunostimulant containing extract from pleurotus cornucopiae as active ingredient Download PDF

Info

Publication number
WO2006038527A1
WO2006038527A1 PCT/JP2005/018004 JP2005018004W WO2006038527A1 WO 2006038527 A1 WO2006038527 A1 WO 2006038527A1 JP 2005018004 W JP2005018004 W JP 2005018004W WO 2006038527 A1 WO2006038527 A1 WO 2006038527A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
cells
tumor
active ingredient
mushroom
Prior art date
Application number
PCT/JP2005/018004
Other languages
French (fr)
Japanese (ja)
Inventor
Tokushiro Yoshinari
Kazunori Kato
Original Assignee
Three B Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Three B Co., Ltd. filed Critical Three B Co., Ltd.
Priority to JP2006539248A priority Critical patent/JPWO2006038527A1/en
Publication of WO2006038527A1 publication Critical patent/WO2006038527A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/07Basidiomycota, e.g. Cryptococcus
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to an antitumor immunostimulant and an immune-stimulated health food comprising a potato extract as an active ingredient.
  • the biological defense mechanisms by the immune system include innate immunity and acquired immunity.
  • Innate immunity is a mechanism mainly composed of macrophages and leukocytes that eliminates pathogenic bacteria and other patterns by recognizing and preying on them, whereas acquired immunity is a variety of T cells and B cells. It is an immune response that can deal with each foreign antigen.
  • the immune response reacts as powerfully and efficiently as the living body is exposed to the antigen, preventing re-infection of viruses and the like.
  • inflammatory tissue damage and autoimmune diseases occur frequently when the immune response is constantly active in the body, and the immune response is negatively controlled in the body.
  • Cells, or suppressor T cells are involved in maintaining autoimmune tolerance in normal individuals in the normal state.
  • suppressor T cells inhibit an effective immune response against tumor cells (cancer cells) generated from self in normal individuals. That is, it is considered that the cells involved in autoimmunity are also tolerant to tumor cells. In fact, experimentally removing inhibitory ⁇ cells from normal individuals induces or enhances the immune response to the tumor and can exert an antitumor effect.
  • Inhibitory T cells present in normal individuals are classified as CD25 or GITR (Glucocorticoid-induced TNFR family gene) and FoxP3 gene positive cells contained in the CD4 positive T cell group. Therefore, inhibitory T cells present in lymphoid tissues (spleen, lymph nodes, peripheral blood, bone marrow) in normal individuals can be analyzed with CD4 and CD25, GITR or FoxP3 molecule-positive cells. When the proportion of inhibitory T cells increases in vivo, the immune response to tumors, viruses, pathogenic bacteria, etc. immediately decreases as soon as the individual falls into immune tolerance or immunosuppression.
  • GITR Glucocorticoid-induced TNFR family gene
  • an immunomodulator capable of suppressing the increase in immunosuppressive T cells is considered useful as an active ingredient of an immunostimulator.
  • Prior art document information relating to the present invention includes the following: JP-A-11 302 191 and Asahi Misaki et al., "Chemical properties and anti-polysaccharides of edible mushrooms (Oyster mushrooms, Tamogitake)” Oncology ”, Bulletin of Osaka City University School of Life Sciences, 39th (1991), p. 1-8. Disclosure of the invention
  • An object of the present invention is to provide a drug having an immunostimulatory action and a functional food that are extremely safe.
  • the present invention provides an antitumor immunostimulant comprising a potato extract as an active ingredient.
  • the present invention relates to a tumor cell comprising an extract of rice cake as an active ingredient.
  • a vesicle growth inhibitor is provided.
  • Tumor cells include tumors in the human body, such as cervical cancer, leukemia, lymphoma, myeloma, melanoma, spleen cancer, prostate cancer, head and neck cancer, breast cancer, lung cancer, colon cancer, stomach cancer, esophageal cancer, Ovarian cancer, squamous cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, mesothelioma and epidermoid carcinoma-derived cells, tumor cells transplanted into experimental animals such as mice, and cells of cell lines derived from human tumors, such as HeLa , MeWo, Hs695T, A137, KATO-III, MKN 45, MKN28, HuH28, Daudi, Ramos, Raji, U937, HS— Sultan, SKM— 1, THP— 1, IM— 9, MM1S, K562, HL60, HSC— 3, HSC— 4, TTn, TE-10, IMR-32, U251, PC-3, LNC
  • the present invention provides an agent for enhancing the production of immunostimulatory site force-in comprising a potato extract as an active ingredient.
  • immunostimulatory site-in include, for example, interleukin (IL) 1, 2, 3, 4, 5, 6, 7, 12, 15, 18, 21, 23, interferon (IFN) ⁇ , j8, ⁇ , Tumor necrosis factor (TNF) ⁇ , ⁇ .
  • IFN interferon
  • TNF Tumor necrosis factor
  • the present invention provides an immunosuppressive sputum cell growth inhibitor comprising a potato extract as an active ingredient.
  • the present invention provides an immune-stimulated health food comprising a potato extract and a health food for suppressing tumor cell growth.
  • Figure 1 shows the inhibition of HeLa cell growth by the hot water extract of potato.
  • FIG. 2 shows the inhibition of tumor cell Sarcomal 80 growth by hot water extract of taro.
  • FIG. 3 shows an increase in activated antigen expression of human rod-shaped cells by the extract of hot water from potato.
  • FIG. 4 shows the enhancement of IL-12 production of human rod-like cell force by the hot water extract of potato.
  • FIG. 5 shows the results of FACS analysis of inhibitory T cells in mouse spleen cells.
  • FIG. 6 shows the ratio of GITR positive inhibitory T cells in the spleen of Sarcomal80 tumor-bearing mice.
  • FIG. 7 shows the change in tumor volume of Sarcomal 80-transplanted mice that received the hot water extract of potato and other mushrooms.
  • FIG. 8 shows the mean tumor weight of Sarcomal 80-transplanted mice that received the hot water extract of potato and other mushrooms.
  • FIG. 9 shows the survival rate of Sarcomal 80 transplanted mice fed with hot water extract of potato and other mushrooms.
  • Tamogi mushroom is a mushroom belonging to the genus Oyster mushroom and is widely used for food mainly in Hokkaido.
  • the bamboo shoot extract can be produced by the following method.
  • the bamboo shoots used in the present invention may be artificially cultivated at a factory where natural products can be harvested.
  • the bamboo shoots are preferably used within 2 hours after harvest.
  • the extraction is preferably performed by hot water extraction.
  • the harvested bamboo shoots are put into boiling water 2-30 times, preferably 5-20 times the weight of the bamboo shoots, and stirred while adding steam. Extract the rice cake extract while boiling and stirring for 10 minutes.
  • the obtained extract may be used as it is or may be filtered to remove the solid content. Further, it may be appropriately concentrated using a vacuum concentrator, a freeze concentrator or the like.
  • it may be powdered by freeze-drying or spray-drying, for example, by sterilizing at 120 ° C. for 15 minutes after enclosing in the retort pack.
  • the rice cake extract obtained as described above suppresses the growth of cell lines derived from human cancers such as HeLa cells, as shown in the Examples below, and is used to suppress sarcoma transplanted into mice. We were able to inhibit growth.
  • the extract of coconut husk enhances the production of immunostimulatory sites such as IL-12, activates rod cells, and inhibits the appearance of immunosuppressive T cells. It was.
  • the bamboo shoot extract obtained in accordance with the present invention can be used as it is as an immunostimulating health food or a health food for suppressing tumor cell growth. Good.
  • 0.1-lOmlZkgZ day as an extract with a solid content of 2.5%, especially 1. 8- 2. 7mlZkgZ day is appropriate.
  • the immunostimulant according to the present invention has advantages such as being non-toxic and having no adverse effect on the living body even when ingested in large amounts, and thus is very suitable for addition to health foods. Yes.
  • the contents of all patents and references explicitly cited herein are hereby incorporated by reference as part of the present specification.
  • the contents described in the specification and drawings of Japanese Patent Application No. 2004-290528, which is the application on which the priority of the present application is based, are cited herein as part of this specification.
  • Hot water extracts of various mushrooms were prepared. Each lkg of bamboo shoots, maitake mushrooms, shimeji mushrooms and shitake mushrooms was placed in 5 kg of boiling water, further heated, boiled and stirred for 10 minutes. The obtained extract was concentrated under reduced pressure to obtain 240 ml of a 2.5% solid concentrate. The resulting concentrate was subjected to a retort sterilization treatment at 120 ° C. for 15 minutes to obtain a mushroom hot water extract.
  • the hot water extract of bamboo shoots produced in Example 1 was further concentrated under reduced pressure to prepare a triple concentration of bamboo shoot extract, which was used to measure HeLa cell growth inhibitory activity.
  • HeLa cells were seeded in MEM medium in 96-well microplates with 3.7xl0 3 cell Zwell, and Tamogi salmon extract had final solid concentrations of 1.25%, 2.5%, 2.75% and 3 respectively. Incubated at 37 ° C with 75%. After 12, 24, and 48 hours, the cell number was counted at 450 nm by the MTT method.
  • 0.1 ml of cell solution (about 5 ⁇ 10 6 cells) was transplanted into the abdominal cavity of 5 female mice (Sic: ICR), and sacrificed by cervical dislocation 7 days later. The abdomen was disinfected with ethanol, and ascites was collected using a sterile syringe. Ascites collected from each animal force was mixed, and about 5 ⁇ 10 6 cells were transplanted subcutaneously into the wind diameter of female mice (Slc: ICR, 5 weeks old, about 18 g).
  • Tumor volume was measured on days 5, 7, 10, 14, 17, 21, and 22 after transplantation. Tumor volume is
  • the minor axis (a) and the major axis (b) of the tumor were measured using a caliper, calculated by the following formula, and expressed as an average standard deviation.
  • Tumor volume (cm 3 ) 4/3 ⁇ a3 ⁇ 4 / 2
  • Induction of human peripheral blood mononuclear cell-derived rod-shaped cells was prepared according to the method described in Kato et al. (K. Kato, et al., J Leukoc Biol, 70: 941-949, 2001). First, 15-20 ml of blood was collected from the left arm vein of a healthy person using a syringe with heparin, and diluted with an equal amount of PBS under aseptic conditions. The same-diluted blood was layered on Lymphosepar 15 ml (manufactured by IBL) prepared in a sterile plastic tube in advance, and centrifuged at 1500 rpm for 30 minutes.
  • Lymphosepar 15 ml manufactured by IBL
  • the mononuclear cell layer on Lymphosepar was collected, and the cells were washed twice by centrifugation with PBS.
  • the mononuclear cells were finally diluted in RPMI 1640 medium containing 10% urine fetal serum (manufactured by Sigma), and the cells were added to a 10 cm plastic petri dish and cultured.
  • non-adherent cells lymphocytes
  • adherent cells mononuclear cells
  • rod-shaped cell induction medium RPMI1640 medium, 10% urine fetal serum, 50 ngZml human GM— CSF (manufactured by Osteogenetics) and 50 ng / ml human IL-4 (manufactured by Osteogenetics)
  • rod-shaped cell induction medium RPMI1640 medium, 10% urine fetal serum, 50 ngZml human GM— CSF (manufactured by Osteogenetics) and 50 ng / ml human IL-4 (manufactured by Osteogenetics)
  • the induced rod-shaped cells were collected in a plastic tube, and RPMI1640 medium was added to perform centrifugation, and the number of cells was measured.
  • the cell concentration was finally adjusted to 2xl0 5 Zml with RPMI 16 40 medium, 0.5 ml each was added to the 24-well plate, and various mushroom hot water extracts prepared in Example 1 (Tamogi mushroom, maitake, shimeji mushroom) , Shitake) was added at a final concentration of 2%, and cultured at 37 ° C for 24 hours.
  • Spider cells stimulated with mushroom hot water extract were collected in a plastic tube, centrifuged and washed with RPMI1640 medium, FITC-labeled anti-human CD45 antibody, PE-labeled anti-human CD86 antibody (both manufactured by eBioscience) 5 ⁇ l of each was added, reacted at 4 ° C. for 1 hour, and analyzed for changes in the expression of cell surface antigens using FACS (BD).
  • CD54 and CD86 in rod cells are molecules indispensable for eliciting an immune response, and it is known that an increase in antigen expression indicates the activity state of rod cells. As a result, as shown in FIG.
  • Example 1 The various mushroom hot water extracts produced in Example 1 were used to examine the effect of enhancing IL-12 production from human rod-like cells.
  • Interleukin 12 (IL-12) is a type of cytodynamic force produced mainly by rod-like cell force, and is known to be the most important factor for the activity of NK cells and Thl cells. .
  • the cell concentration of the rod-shaped cells induced in the same manner as in Example 4 was finally adjusted to 2xl0 5 Zml with RPMI1640 medium, and 0.5 ml was added to each 24 well plate.
  • CD40 ligand gene transfer by adenovirus was performed, and various mushroom hot water extracts (Tamogi mushrooms, mitake mushrooms, shimeji mushrooms) It was added at 2% and cultured at 37 ° C for 48 hours.
  • mice were 5 weeks old animals purchased from S1 ICR SPF male mice (Japan SLC Co., Ltd.). The breeding room was maintained at an average temperature of 22 ° C and humidity of 50%. Five million cells of Sarcomal80 cells shown in Example 3 were administered subcutaneously to the thigh of ICR mice using an lml syringe and 26G (Terumo).
  • Example 1 On the same day of transplantation, the test substance tofu-mushroom extract prepared in Example 1 was forcibly administered into the stomach with a metal sonde for mice up to the 21st day every day. As a control group, an equal amount of physiological saline (Otsuka Pharmaceutical Co., Ltd.) was administered. Seven mice were used per group. The tumor system was measured twice a week after transplantation, and the tumor volume was measured until 21 days later. As a result, a significant tumor growth inhibitory effect was observed in the group treated with hot water extract. This result was the same as the growth suppression shown in Example 3, and the antitumor effect was reconfirmed.
  • physiological saline Oletsuka Pharmaceutical Co., Ltd.
  • mice On day 22 after tumor transplantation, all tumor-transplanted mice were euthanized under deep anesthesia, and the spleen was removed from the abdominal cavity. The isolated spleen was loosened in a petri dish filled with a culture solution to obtain a spleen cell solution mainly composed of lymphocytes. After red blood cells in the obtained spleen cells were hemolyzed, the number of cells was measured, and 100,000 cells were placed in a plastic tube.
  • mice treated with the hot water extract of Tamogi had a larger spleen and mild fibroblasts than mice given saline.
  • Fluorescent staining of inhibitory T cells in spleen cells was performed as follows. Although 7 mice in each treatment group were analyzed, inhibitory T cells were analyzed using 6 of them. The experiment number of each mouse is as follows.
  • Group 2 Tamogitake hot water extract administration group
  • FITC-CD4 (RM4-5; 0.5 ⁇ 1 / reaction, eBioscience), Biotin-uITR (DTA— 1; 0.5 ⁇ 1 / reaction, eBioscience, Avidine— PE (0.2 ⁇ 1 / rea ction, BDpharmingen) and allowed to react for 1 hour at 4 ° C After washing cells with PBS, dead cells were removed with PI staining, and FACScalibur (BD Biosciences) was used. The number of inhibitory T cells was analyzed using Flowjo software (Trister).
  • Inhibitory T cells were calculated from the percentage of GITR positive cells in CD4 positive T cells (FITC positive cells). The results are shown in Figs. GITR-positive suppressor T cells were significantly reduced in the tumor-bearing mice group (13.2% ⁇ 3.1%) treated with the extract of hot water extract compared to the tumor-bearing mice treated with saline (33.4% ⁇ 10.6%) Turned out to be.
  • the hot water extract of scallops contains an active substance that can inhibit the appearance of immunosuppressive T cells induced by the cancer-bearing state. This indicates that the bamboo shoot extract is useful as an immunostimulator.
  • the prophylactic anti-tumor effect of Sarcomal 80 was measured using the hot water extract of the bamboo shoot and the commercial mushroom extract.
  • the hot spring water extract (lots 1 and 2), Agaritas Sengyo-ro Royal and Meshima (registered trademark) Pure PL2.5 produced in Example 1 were used.
  • Sarcomal80 frozen cells (TKG0173, obtained from Tohoku University Institute of Aging Medicine) are rapidly thawed with 37 ° C warm water, added with approximately 10 volumes of physiological saline, and centrifuged (1000 rpm Z). And 5 minutes) and the supernatant was removed. After repeating this operation four times, about 3 times the amount of physiological saline was added to the pellet and stirred to obtain a cell solution.
  • 0.1 ml of cell solution (about 5 ⁇ 10 6 cells) was transplanted into the abdominal cavity of mice and sacrificed by cervical dislocation 7 days later. The abdomen was disinfected with ethanol, and ascites was collected using a sterile syringe. Ascites fluid collected from each animal was mixed, and about 5 ⁇ 10 6 cells were transplanted subcutaneously into the wind diameter portion of the test animal.
  • test animals 6-week-old female mice (Sic: ICR) were used, 10 in each group, and food and water were freely fed.
  • Test solution once a day for 10 days before tumor transplantation and 35 days after transplantation The solution was administered orally. The administration was carried out by forcibly administering a predetermined amount of hot water extract of hot spring or control mushroom extract and 12 ml Zkg of test solution having purified hydropower into the stomach of transplanted animals using a metal sonde for mice. The dosage is as shown in the table below.
  • Tumor volume was measured on surviving individuals on the day of the experiment, on days 5, 7, 10, 14, 17, 21, 24, 28, 32 and 36 (end of observation) after transplantation.
  • the tumor volume was calculated by the following formula after measuring the short axis (a) and long axis (b) of the tumor using calipers.
  • Tumor volume (cm 3 ) 4/3 ⁇ a3 ⁇ 4 / 2
  • Tumor weight was measured immediately after discovery in the case of death, and the day after the final administration (day 35 after transplantation) in the case of survival.
  • the test animals were euthanized by exsanguination under ether anesthesia, and the tumor in the left inguinal region was excised and weighed. Based on the average value of the tumor weight of each test group, each tumor growth inhibition rate was calculated by the following formula.
  • Tumor growth inhibition rate (%) (1—average tumor weight in the treated group Z average tumor weight in the control group) X 10 0
  • the survival rate was calculated by the following formula after examining the survival days of the test animals after tumor transplantation.
  • the mean value of the tumor volume increased daily, but remained at a lower value than in the control group, and was statistically different from the control group intermittently after the fifth day after transplantation. The value was significantly lower.
  • the mean value of tumor weight was 5.7% of tumor growth inhibition compared to the control group, and no statistically significant difference was observed.
  • the survival rate was 20.6%.
  • the survival time was statistically significant compared to the control group.
  • the mean tumor weight was 24.6% less tumor growth than the control group, and no statistically significant difference was observed.
  • the survival rate was 8.9%. There was no statistically significant difference in the days of survival compared with the control group.
  • the antitumor immunostimulatory agent of the present invention is useful for suppressing the growth of tumor cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Pulmonology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

An antitumor immunostimulant containing an extract from Pleurotus cornucopiae as an active ingredient. It has been proved that the extract from Pleurotus cornucopiae suppresses the multiplication of tumor cells, increases the production of immunostimulatory cytokine and suppresses the increase of immunosuppressive T cells. Further, there is provided an immunostimulatory health food, or tumor cell amplification suppressive health food, comprising the extract from Pleurotus cornucopiae.

Description

明 細 書  Specification
たもぎ茸抽出物を有効成分とする抗腫瘍性免疫賦活剤  Anti-tumor immunostimulant containing tamogi mushroom extract as active ingredient
技術分野  Technical field
[0001] 本発明は、たもぎ茸抽出物を有効成分とする抗腫瘍性免疫賦活剤および免疫賦 活用健康食品に関する。  [0001] The present invention relates to an antitumor immunostimulant and an immune-stimulated health food comprising a potato extract as an active ingredient.
背景技術  Background art
[0002] キノコ類の生体免疫賦活作用についてはさまざまな報告がされており、免疫賦活の 機作ゃキノコ種の違いによる生理活性の差などが徐々に明らかにされている。これま でにある種のキノコ類に含有される多糖体が抗癌の目的で製品化され使用されてい るが、その効果は必ずしも充分なものとはいえず、より有用な免疫賦活剤が望まれて いた。  [0002] Various reports have been made on the bioimmunity-stimulating action of mushrooms, and the mechanism of immunostimulation has gradually revealed the difference in physiological activity due to the difference in mushroom species. So far, polysaccharides contained in certain types of mushrooms have been commercialized and used for anti-cancer purposes, but their effects are not always sufficient, and more useful immunostimulants are desired. It was rare.
[0003] 近年、各種感染症、癌などに対する薬剤による治療法が開発され、その有用性が 見!ヽだされて 、るが、癌化学療法や癌免疫療法も満足すべき結果は得られて 、な 、 。これら疾患の発症は免疫担当細胞類の活性低下に起因するところが大きい。この ため、免疫担当細胞に対して免疫賦活効果を有する組成物は、これらの疾患の予防 や治療に極めて有用であり、健康維持の観点からも重要である。  [0003] In recent years, treatments with drugs for various infectious diseases and cancers have been developed and their usefulness has been found! However, cancer chemotherapy and cancer immunotherapy have also achieved satisfactory results. ,,,. The onset of these diseases is largely due to decreased activity of immunocompetent cells. Therefore, a composition having an immunostimulatory effect on immunocompetent cells is extremely useful for the prevention and treatment of these diseases, and is also important from the viewpoint of maintaining health.
[0004] 免疫系による生体防御機構には自然免疫と獲得免疫がある。自然免疫はマクロフ ァージ、白血球が主体となり病原性細菌等のパターンを認識し捕食することにより生 体内から排除する機構であるのに対して、獲得免疫は T細胞と B細胞を主体とした多 様な異物抗原にそれぞれ対応できる免疫応答である。その免疫応答は抗原に生体 が暴露されるほど強力かつ効率的に反応し、ウィルスなどの再感染を防御している。 しかしながら免疫応答が生体内で常に活発に行われていると、逆に炎症性組織障害 や自己免疫性疾患が多発することが示されており、生体内にはその免疫応答を"負" に制御できる細胞、つまり抑制性 T細胞が正常個体中に自然状態で自己免疫寛容 の維持に関与している。  [0004] The biological defense mechanisms by the immune system include innate immunity and acquired immunity. Innate immunity is a mechanism mainly composed of macrophages and leukocytes that eliminates pathogenic bacteria and other patterns by recognizing and preying on them, whereas acquired immunity is a variety of T cells and B cells. It is an immune response that can deal with each foreign antigen. The immune response reacts as powerfully and efficiently as the living body is exposed to the antigen, preventing re-infection of viruses and the like. However, it has been shown that inflammatory tissue damage and autoimmune diseases occur frequently when the immune response is constantly active in the body, and the immune response is negatively controlled in the body. Cells, or suppressor T cells, are involved in maintaining autoimmune tolerance in normal individuals in the normal state.
[0005] 最近の研究で自然状態に存在する抑制性 T細胞の異常がヒトの自己免疫性疾患、 炎症性腸炎、アレルギーの直接原因となることが示されている。この抑制性 T細胞の 機能を強化できれば自己免疫病やアレルギー、さらには移植臓器に対する免疫拒 絶反応の制御も期待できる。 [0005] Recent studies have shown that naturally occurring inhibitory T cell abnormalities directly cause human autoimmune diseases, inflammatory bowel disease, and allergies. Of this suppressor T cell If the function can be strengthened, it can be expected to control autoimmune diseases, allergies, and immune rejection of transplanted organs.
[0006] 一方、抑制性 T細胞は正常個体中で自己から発生した腫瘍細胞 (癌細胞)に対す る有効な免疫反応を阻害していることが示されている。すなわち自己免疫寛容に関 与する細胞が腫瘍細胞に対しても寛容であることが考えられる。実際に正常個体から 抑制性 τ細胞を実験的に除去すると腫瘍に対する免疫応答が惹起あるいは強化さ れ抗腫瘍効果が発揮できる。  [0006] On the other hand, it has been shown that suppressor T cells inhibit an effective immune response against tumor cells (cancer cells) generated from self in normal individuals. That is, it is considered that the cells involved in autoimmunity are also tolerant to tumor cells. In fact, experimentally removing inhibitory τ cells from normal individuals induces or enhances the immune response to the tumor and can exert an antitumor effect.
[0007] 正常個体に存在する抑制性 T細胞は CD4陽性 T細胞群に含まれる CD25または G ITR(Glucocorticoid- induced TNFR family gene)および FoxP3遺伝子陽性細胞とし て分類されている。そのため正常個体中のリンパ組織 (脾臓、リンパ節、末梢血、骨 髄)に存在する抑制性 T細胞は CD4と CD25、 GITRまたは FoxP3分子の発現陽性 細胞で解析することが可能である。抑制性 T細胞の割合が生体内で増カロして 、るとき は個体が免疫寛容もしくは免疫抑制状態に陥りやすぐ腫瘍、ウィルス、病原性細菌 等に対する免疫応答も低下する。  [0007] Inhibitory T cells present in normal individuals are classified as CD25 or GITR (Glucocorticoid-induced TNFR family gene) and FoxP3 gene positive cells contained in the CD4 positive T cell group. Therefore, inhibitory T cells present in lymphoid tissues (spleen, lymph nodes, peripheral blood, bone marrow) in normal individuals can be analyzed with CD4 and CD25, GITR or FoxP3 molecule-positive cells. When the proportion of inhibitory T cells increases in vivo, the immune response to tumors, viruses, pathogenic bacteria, etc. immediately decreases as soon as the individual falls into immune tolerance or immunosuppression.
[0008] したがって、免疫抑制性 T細胞の増加を抑制しうる免疫調整物質は免疫賦活剤の 有効成分として有用であると考えられる。  [0008] Therefore, an immunomodulator capable of suppressing the increase in immunosuppressive T cells is considered useful as an active ingredient of an immunostimulator.
[0009] 本発明に関連する先行技術文献情報としては以下のものがある:特開平 11 302 191、および三崎旭ら、「キシメジ科食用茸 (ヒラタケ、タモギタケ)の多糖の化学的性 質及び抗腫瘍作用」、大阪市立大学生活科学部紀要、第 39卷(1991)、 p. 1— 8。 発明の開示  [0009] Prior art document information relating to the present invention includes the following: JP-A-11 302 191 and Asahi Misaki et al., "Chemical properties and anti-polysaccharides of edible mushrooms (Oyster mushrooms, Tamogitake)" Oncology ”, Bulletin of Osaka City University School of Life Sciences, 39th (1991), p. 1-8. Disclosure of the invention
発明が解決しょうとする課題  Problems to be solved by the invention
[0010] 本発明は、安全性が極めて高い、免疫賦活作用を有する薬剤ならびに機能性食 品を提供することを目的とする。 [0010] An object of the present invention is to provide a drug having an immunostimulatory action and a functional food that are extremely safe.
課題を解決するための手段  Means for solving the problem
[0011] 本発明者らは、北海道産の食用キノコから免疫賦活作用を有するキノコを検索した 結果、たもぎ茸の抽出物に高い免疫賦活作用があることを見いだした。 [0011] As a result of searching for mushrooms having an immunostimulatory effect from edible mushrooms produced in Hokkaido, the present inventors have found that an extract of Tamogi mushroom has a high immunostimulatory effect.
[0012] すなわち、本発明は、たもぎ茸抽出物を有効成分とする抗腫瘍性免疫賦活剤を提 供する。別の態様においては、本発明は、たもぎ茸抽出物を有効成分とする腫瘍細 胞増殖抑制剤を提供する。腫瘍細胞としては、ヒトの体内の腫瘍、例えば、子宮頸部 癌、白血病、リンパ腫、骨髄腫、黒色種、脾臓癌、前立腺癌、頭頸部癌、乳癌、肺癌 、大腸癌、胃癌、食道癌、卵巣癌、扁平上皮癌、肝細胞癌、胆管癌、中皮腫および 類表皮癌由来細胞、マウス等の実験動物に移植された腫瘍細胞、ならびにヒト腫瘍 に由来する細胞株の細胞、例えば、 HeLa、 MeWo, Hs695T, A137, KATO-III, MKN 45, MKN28, HuH28, Daudi, Ramos, Raji, U937, HS— Sultan, SKM— 1 , THP— 1 , IM— 9, MM1S, K562, HL60, HSC— 3, HSC— 4, TTn, TE- 10, IMR-32, U251 , PC- 3, LNCaP, DU145, DLD-1 , WiDr, SW837, Lul35, IMR-90, A549, SK— OV— 3, SK— Br— 3, A431 , RMG-1 , MCF-7, MIAPaCa- 2, AsPCl , KP- 4が含まれる。また別の態様においては、 本発明は、たもぎ茸抽出物を有効成分とする免疫賦活性サイト力インの産生の増強 剤を提供する。免疫賦活性サイト力インとしては、例えば、インターロイキン (IL)1、 2、 3、 4、 5、 6、 7、 12、 15、 18、 21、 23、インターフェロン (IFN) α、 j8、 γ、腫瘍壊死因 子 (TNF) α、 β、が挙げられる。また別の態様においては、本発明は、たもぎ茸抽出 物を有効成分とする免疫抑制性 Τ細胞増加の抑制剤を提供する。さらに別の態様に おいては、本発明は、たもぎ茸抽出物からなる免疫賦活用健康食品ならびに腫瘍細 胞増殖抑制用健康食品を提供する。 [0012] That is, the present invention provides an antitumor immunostimulant comprising a potato extract as an active ingredient. In another aspect, the present invention relates to a tumor cell comprising an extract of rice cake as an active ingredient. A vesicle growth inhibitor is provided. Tumor cells include tumors in the human body, such as cervical cancer, leukemia, lymphoma, myeloma, melanoma, spleen cancer, prostate cancer, head and neck cancer, breast cancer, lung cancer, colon cancer, stomach cancer, esophageal cancer, Ovarian cancer, squamous cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, mesothelioma and epidermoid carcinoma-derived cells, tumor cells transplanted into experimental animals such as mice, and cells of cell lines derived from human tumors, such as HeLa , MeWo, Hs695T, A137, KATO-III, MKN 45, MKN28, HuH28, Daudi, Ramos, Raji, U937, HS— Sultan, SKM— 1, THP— 1, IM— 9, MM1S, K562, HL60, HSC— 3, HSC— 4, TTn, TE-10, IMR-32, U251, PC-3, LNCaP, DU145, DLD-1, WiDr, SW837, Lul35, IMR-90, A549, SK— OV— 3, SK— Br— 3, A431, RMG-1, MCF-7, MIAPaCa-2, AsPCl, KP-4. In another aspect, the present invention provides an agent for enhancing the production of immunostimulatory site force-in comprising a potato extract as an active ingredient. Examples of immunostimulatory site-in include, for example, interleukin (IL) 1, 2, 3, 4, 5, 6, 7, 12, 15, 18, 21, 23, interferon (IFN) α, j8, γ, Tumor necrosis factor (TNF) α, β. In another aspect, the present invention provides an immunosuppressive sputum cell growth inhibitor comprising a potato extract as an active ingredient. In still another aspect, the present invention provides an immune-stimulated health food comprising a potato extract and a health food for suppressing tumor cell growth.
図面の簡単な説明 Brief Description of Drawings
図 1は、たもぎ茸熱水抽出物による HeLa細胞増殖の抑制を示す。  Figure 1 shows the inhibition of HeLa cell growth by the hot water extract of potato.
図 2は、たもぎ茸熱水抽出物による腫瘍細胞 Sarcomal80の増殖の抑制を示す。 図 3は、たもぎ茸熱水抽出物によるヒト榭状細胞の活性化抗原発現の増加を示す。 図 4は、たもぎ茸熱水抽出物によるヒト榭状細胞力もの IL— 12産生の増強を示す。 図 5は、マウス脾細胞中の抑制性 T細胞の FACS解析の結果を示す。  Fig. 2 shows the inhibition of tumor cell Sarcomal 80 growth by hot water extract of taro. FIG. 3 shows an increase in activated antigen expression of human rod-shaped cells by the extract of hot water from potato. FIG. 4 shows the enhancement of IL-12 production of human rod-like cell force by the hot water extract of potato. FIG. 5 shows the results of FACS analysis of inhibitory T cells in mouse spleen cells.
図 6は、 Sarcomal80担癌マウス脾臓中における GITR陽性抑制性 T細胞の割合 を示す。  FIG. 6 shows the ratio of GITR positive inhibitory T cells in the spleen of Sarcomal80 tumor-bearing mice.
図 7は、たもぎ茸熱水抽出物および他のキノコ抽出物を与えた Sarcomal80移植 マウスの腫瘍体積の変化を示す。  FIG. 7 shows the change in tumor volume of Sarcomal 80-transplanted mice that received the hot water extract of potato and other mushrooms.
図 8は、たもぎ茸熱水抽出物および他のキノコ抽出物を与えた Sarcomal80移植 マウスの腫瘍重量の平均値を示す。 図 9は、たもぎ茸熱水抽出物および他のキノコ抽出物を与えた Sarcomal80移植 マウスの生存率を示す。 FIG. 8 shows the mean tumor weight of Sarcomal 80-transplanted mice that received the hot water extract of potato and other mushrooms. FIG. 9 shows the survival rate of Sarcomal 80 transplanted mice fed with hot water extract of potato and other mushrooms.
発明を実施するための最良の形態  BEST MODE FOR CARRYING OUT THE INVENTION
[0014] たもぎ茸はヒラタケ属に属するキノコであり、北海道を中心として広く食用に供され ている。たもぎ茸抽出物は以下の方法によって製造することができる。本発明におい て使用するたもぎ茸は、天然に産するものを収穫してもよぐ工場で人工栽培してもよ い。たもぎ茸は、好ましくは、収穫後 2時間以内に使用する。  [0014] Tamogi mushroom is a mushroom belonging to the genus Oyster mushroom and is widely used for food mainly in Hokkaido. The bamboo shoot extract can be produced by the following method. The bamboo shoots used in the present invention may be artificially cultivated at a factory where natural products can be harvested. The bamboo shoots are preferably used within 2 hours after harvest.
[0015] 収穫したたもぎ茸から有効成分を抽出する。抽出は好ましくは熱水抽出により行う。  [0015] Extract active ingredients from the harvested bamboo shoots. The extraction is preferably performed by hot water extraction.
例えば、収穫したたもぎ茸を、たもぎ茸の重量の 2— 30倍、好ましくは 5— 20倍量の 沸騰水の中に投入し、蒸気を加えながら撹拌する。沸騰してカゝら 10分間撹拌しなが らたもぎ茸エキスを抽出する。得られたエキスはそのまま使用してもよぐ濾過して固 形分を除いてもよい。また、減圧濃縮機、凍結濃縮機等を用いて適宜濃縮してもよい 。また、エキスを長期間保存するためには、レトルトパックに封入した後、例えば、 120 °C、 15分間で殺菌処理をしてもよぐ凍結乾燥または噴霧乾燥により粉末としてもよ い。  For example, the harvested bamboo shoots are put into boiling water 2-30 times, preferably 5-20 times the weight of the bamboo shoots, and stirred while adding steam. Extract the rice cake extract while boiling and stirring for 10 minutes. The obtained extract may be used as it is or may be filtered to remove the solid content. Further, it may be appropriately concentrated using a vacuum concentrator, a freeze concentrator or the like. In order to store the extract for a long period of time, it may be powdered by freeze-drying or spray-drying, for example, by sterilizing at 120 ° C. for 15 minutes after enclosing in the retort pack.
[0016] このようにして得られたたもぎ茸抽出物は、後述の実施例で示されるように、 HeLa 細胞などのヒト癌に由来する細胞株の増殖を抑制し、マウスに移植した肉腫の成長を 阻害することができた。さらに、たもぎ茸抽出物が、 IL— 12などの免疫賦活性サイト 力インの産生を増強し、榭状細胞を活性化させ、免疫抑制性 T細胞の出現を阻害しう ることが示された。これらの結果は、本発明にしたがうたもぎ茸抽出物が、免疫賦活活 性および腫瘍細胞増殖抑制活性を有することを裏付ける。  [0016] The rice cake extract obtained as described above suppresses the growth of cell lines derived from human cancers such as HeLa cells, as shown in the Examples below, and is used to suppress sarcoma transplanted into mice. We were able to inhibit growth. In addition, it has been shown that the extract of coconut husk enhances the production of immunostimulatory sites such as IL-12, activates rod cells, and inhibits the appearance of immunosuppressive T cells. It was. These results confirm that the extract of eel paste according to the present invention has immunostimulatory activity and tumor cell growth inhibitory activity.
[0017] 本発明にしたがって得られたたもぎ茸抽出物は、そのまま免疫賦活用健康食品あ るいは腫瘍細胞増殖抑制用健康食品として用いることができる力 他の食品に添カロ して用いてもよい。摂取量は、固形分 2. 5%のエキスとして 0. 1— lOmlZkgZ日、 特に 1. 8- 2. 7mlZkgZ日が適当である。  [0017] The bamboo shoot extract obtained in accordance with the present invention can be used as it is as an immunostimulating health food or a health food for suppressing tumor cell growth. Good. As for the intake, 0.1-lOmlZkgZ day as an extract with a solid content of 2.5%, especially 1. 8- 2. 7mlZkgZ day is appropriate.
[0018] 本発明にしたがう免疫賦活剤は、毒性を有しないこと、多量に摂取しても生体に悪 影響を与えないことなどの利点を有するため、健康食品に添加するのに非常に適し ている。 [0019] 本明細書において明示的に引用される全ての特許および参考文献の内容は全て 本明細書の一部としてここに引用する。また,本出願が有する優先権主張の基礎とな る出願である日本特許出願 2004— 290528号の明細書および図面に記載の内容 は全て本明細書の一部としてここに引用する。 [0018] The immunostimulant according to the present invention has advantages such as being non-toxic and having no adverse effect on the living body even when ingested in large amounts, and thus is very suitable for addition to health foods. Yes. [0019] The contents of all patents and references explicitly cited herein are hereby incorporated by reference as part of the present specification. In addition, the contents described in the specification and drawings of Japanese Patent Application No. 2004-290528, which is the application on which the priority of the present application is based, are cited herein as part of this specification.
[0020] 以下に実施例により本発明をより詳細に説明するが、本発明はこれらの実施例によ り限定されるものではない。  Hereinafter, the present invention will be described in more detail with reference to examples, but the present invention is not limited to these examples.
実施例 1  Example 1
[0021] キノコ熱 7k抽出物の調製 [0021] Preparation of mushroom heat 7k extract
各種キノコの熱水抽出物を調製した。たもぎ茸、マイタケ、シメジ、およびシィタケ各 lkgをそれぞれ沸騰水 5kg中に入れ、さらに加熱し、沸騰して力も 10分間撹拌した。 得られた抽出液を減圧濃縮して、固形分 2. 5%の濃縮物 240mlを得た。得られた濃 縮物を 120°C、 15分間のレトルト殺菌処理をして、キノコ熱水抽出物を得た。  Hot water extracts of various mushrooms were prepared. Each lkg of bamboo shoots, maitake mushrooms, shimeji mushrooms and shitake mushrooms was placed in 5 kg of boiling water, further heated, boiled and stirred for 10 minutes. The obtained extract was concentrated under reduced pressure to obtain 240 ml of a 2.5% solid concentrate. The resulting concentrate was subjected to a retort sterilization treatment at 120 ° C. for 15 minutes to obtain a mushroom hot water extract.
実施例 2  Example 2
[0022] HeLa細胞増殖抑制活性  [0022] HeLa cell growth inhibitory activity
実施例 1で製造したたもぎ茸熱水抽出物をさらに減圧濃縮して、 3倍濃度のたもぎ 茸エキスを調製し、これを用いて、 HeLa細胞増殖抑制活性を測定した。 HeLa細胞 を 96穴マイクロプレートで MEM培地中に 3. 7xl03細胞 Zゥエルで播種し、たもぎ 茸エキスを最終固形分濃度がそれぞれ 1. 25%、 2. 5%、 2. 75%および 3. 75%と なるようにゥエルに加え、 37°Cで培養した。 12、 24、および 48時間後に、 MTT法に より 450nmで細胞数を係数した。 The hot water extract of bamboo shoots produced in Example 1 was further concentrated under reduced pressure to prepare a triple concentration of bamboo shoot extract, which was used to measure HeLa cell growth inhibitory activity. HeLa cells were seeded in MEM medium in 96-well microplates with 3.7xl0 3 cell Zwell, and Tamogi salmon extract had final solid concentrations of 1.25%, 2.5%, 2.75% and 3 respectively. Incubated at 37 ° C with 75%. After 12, 24, and 48 hours, the cell number was counted at 450 nm by the MTT method.
[0023] 結果を図 1に示す。たもぎ茸エキス添加後 12時間および 24時間では、すべての濃 度で細胞数が減少した。 48時間では 2. 5%濃度以上で細胞数の減少が見られた。 すなわち、たもぎ茸エキスを添加することにより HeLa細胞の増殖が抑制されることが 明らかとなった。なお、対照としてマウス脾臓由来の正常細胞についても同様の実験 を行ったが、たもぎ茸エキスは正常細胞の増殖には影響を及ぼさな力つた。  [0023] The results are shown in FIG. At 12 and 24 hours after addition of the bamboo shoot extract, the cell number decreased at all concentrations. At 48 hours, the number of cells decreased at 2.5% or higher. In other words, it was revealed that the growth of HeLa cells was suppressed by adding the bamboo shoot extract. As a control, the same experiment was performed on normal cells derived from mouse spleen, but Tamogi salmon extract exerted no influence on the growth of normal cells.
実施例 3  Example 3
[0024] 自11重に する^: 11重 ¾ [0024] Make 11 weight ^: 11 ¾
実施例 1で製造したたもぎ茸熱水抽出物の SarcOmal80に対する抗腫瘍効果を 測定した。 Sarcomal80の凍結細胞 (東北大学加齢医学研究所より入手)を、 37°C の温水で急速解凍し、約 10倍量の生理食塩水を加え、遠心分離(1000回転 Z分、 5分間)し、上清を除去した。この操作を 4回繰り返した後、ペレットに約 3倍量の生理 食塩水を加えて撹拌し、細胞液とした。 The antitumor effect of Sagittarius hot water extract produced in Example 1 against Sa rcO mal80 It was measured. Sarcomal80 frozen cells (obtained from Tohoku University Institute of Aging Medicine) are rapidly thawed with 37 ° C warm water, added approximately 10 times the amount of physiological saline, and centrifuged (1000 rpm for 5 minutes). The supernatant was removed. After repeating this operation four times, about 3 times the amount of physiological saline was added to the pellet and stirred to obtain a cell solution.
[0025] 細胞液 0. 1ml (約 5 X 106個の細胞)を雌マウス(Sic : ICR) 5匹の腹腔内に移植し 、 7日後に頸椎脱臼により犠牲死させた。腹部をエタノール消毒し、滅菌した注射筒 を用いて腹水を回収した。各動物力 回収した腹水を混合し、約 5 X 106個の細胞を 雌マウス(Slc :ICR、 5週齢、約 18g)の風径部皮下に移植した。 [0025] 0.1 ml of cell solution (about 5 × 10 6 cells) was transplanted into the abdominal cavity of 5 female mice (Sic: ICR), and sacrificed by cervical dislocation 7 days later. The abdomen was disinfected with ethanol, and ascites was collected using a sterile syringe. Ascites collected from each animal force was mixed, and about 5 × 10 6 cells were transplanted subcutaneously into the wind diameter of female mice (Slc: ICR, 5 weeks old, about 18 g).
[0026] 予防効果の評価実験 (群 1— 3)にお 、ては腫瘍移植前 10日間および移植後 21日 間、治療効果の評価実験 (群 4)においては移植後 21日間、それぞれ 1日 1回試験 溶液を経口投与した。投与は、所定量のたもぎ茸熱水抽出物と精製水力ゝらなる試験 溶液 12mlZkgをマウス用金属ゾンデを用いて移植動物の胃内に強制的に投与す ることにより行った。投与量は以下の表に示すとおりである。  [0026] In the evaluation experiment of the preventive effect (groups 1 to 3), for 10 days before and 21 days after the transplantation, and in the evaluation experiment of the therapeutic effect (group 4), 21 days after the transplantation, each day. Single test solution was administered orally. The administration was performed by forcibly administering 12 mlZkg of a test solution consisting of a predetermined amount of hot water extract of hot water and purified hydropower into the stomach of the transplanted animal using a metal sonde for mice. The dosage is as shown in the table below.
[0027] [表 1]  [0027] [Table 1]
Figure imgf000008_0001
Figure imgf000008_0001
[0028] 移植後 5、 7、 10、 14、 17、 21および 22日目に腫瘍体積を測定した。腫瘍体積は[0028] Tumor volume was measured on days 5, 7, 10, 14, 17, 21, and 22 after transplantation. Tumor volume is
、ノギスを用いて腫瘍の短径 (a)および長径 (b)を測定し、以下の式により算出し、平 均士標準偏差で示した。 The minor axis (a) and the major axis (b) of the tumor were measured using a caliper, calculated by the following formula, and expressed as an average standard deviation.
腫瘍体積 (cm3) =4/3 π a¾/2 Tumor volume (cm 3 ) = 4/3 π a¾ / 2
[0029] 結果を図 2に示す。たもぎ茸熱水抽出物を投与することにより、腫瘍体積の増加が 有意に抑制されることが示された。また、たもぎ茸熱水抽出物を予防的に投与するこ とにより、さらに高い効果が得られることがわ力つた。 [0029] The results are shown in FIG. It was shown that the tumor volume increase was significantly suppressed by administration of the hot water extract of Tamogi. In addition, tamogi hot water extract is administered prophylactically. As a result, it was proved that even higher effects were obtained.
実施例 4  Example 4
[0030] 榭 の rM^J の  [0030] r rM ^ J
ヒト末梢血単核球由来榭状細胞の誘導は、加藤ら(K. Kato, et al., J Leukoc Biol, 70: 941-949, 2001)に記載されている手法に従い調製した。まず、へパリンをカ卩えた シリンジを用いて健常人左腕静脈部より血液 15— 20mlを採取し、無菌下で等量の P BSで希釈した。等倍希釈血液を予め無菌プラスチックチューブに準備したリンフォセ パール 15ml (IBL社製)上に重層し、 1500rpmで 30分間遠心分離した。遠心後、リ ンフォセパール上の単核球層を回収し、 PBSにて細胞を 2回遠心洗浄した。単核球 は最終的に RPMI1640培地、 10%ゥシ胎児血清含(Sigma社製)に希釈し、 10cm のプラスチックシャーレに細胞を添加し培養した。 37°Cで 30分後に非付着性の細胞 (リンパ球)を除去し、付着細胞 (単核球)に対して榭状細胞誘導培地 (RPMI1640 培地、 10%ゥシ胎児血清、 50ngZmlヒト GM— CSF (ォステオジェネテイクス社製) および 50ng/mlヒト IL— 4 (ォステオジェネテイクス社製))にて 37°Cで 7日間培養し 、ヒト単核球由来榭状細胞を誘導した。  Induction of human peripheral blood mononuclear cell-derived rod-shaped cells was prepared according to the method described in Kato et al. (K. Kato, et al., J Leukoc Biol, 70: 941-949, 2001). First, 15-20 ml of blood was collected from the left arm vein of a healthy person using a syringe with heparin, and diluted with an equal amount of PBS under aseptic conditions. The same-diluted blood was layered on Lymphosepar 15 ml (manufactured by IBL) prepared in a sterile plastic tube in advance, and centrifuged at 1500 rpm for 30 minutes. After centrifugation, the mononuclear cell layer on Lymphosepar was collected, and the cells were washed twice by centrifugation with PBS. The mononuclear cells were finally diluted in RPMI 1640 medium containing 10% urine fetal serum (manufactured by Sigma), and the cells were added to a 10 cm plastic petri dish and cultured. After 30 minutes at 37 ° C, non-adherent cells (lymphocytes) were removed, and adherent cells (mononuclear cells) were transformed into rod-shaped cell induction medium (RPMI1640 medium, 10% urine fetal serum, 50 ngZml human GM— CSF (manufactured by Osteogenetics) and 50 ng / ml human IL-4 (manufactured by Osteogenetics)) were cultured at 37 ° C for 7 days to induce human mononuclear cell-derived rod cells.
[0031] 誘導した榭状細胞をプラスチックチューブに回収し、 RPMI1640培地を加えて遠 心洗浄を行い、細胞数を測定した。細胞濃度を最終的に 2xl05個 Zmlに RPMI16 40培地で調整し、 0. 5mlずつ 24穴プレートに添加し、実施例 1で調製した各種キノ コ熱水抽出液 (たもぎ茸、マイタケ、シメジ、シィタケ)をそれぞれ最終濃度 2%で添加 し 37°Cで 24時間培養した。 [0031] The induced rod-shaped cells were collected in a plastic tube, and RPMI1640 medium was added to perform centrifugation, and the number of cells was measured. The cell concentration was finally adjusted to 2xl0 5 Zml with RPMI 16 40 medium, 0.5 ml each was added to the 24-well plate, and various mushroom hot water extracts prepared in Example 1 (Tamogi mushroom, maitake, shimeji mushroom) , Shitake) was added at a final concentration of 2%, and cultured at 37 ° C for 24 hours.
[0032] キノコ熱水抽出液で刺激した榭状細胞をプラスチックチューブに回収し、 RPMI16 40培地で遠心洗浄後、 FITC標識抗ヒト CD45抗体、 PE標識抗ヒト CD86抗体 (い ずれも eBioscience社製)を各 5 μ 1添加し、 4°Cで 1時間反応後、 FACS (BD社製) にて細胞表面抗原の発現変化を解析した。榭状細胞における CD54および CD86 は、免疫応答の惹起に不可欠な分子であり、抗原発現の増加は榭状細胞の活性ィ匕 状態を示すものであることが知られている。その結果、図 3に示すようにたもぎ茸熱水 抽出液を添加した榭状細胞において非添加細胞と比較して CD86抗原の発現増加 (ヒストグラムの右側へのシフト)が確認された。またこの発現増強は他のキノコ抽出液 (マイタケ、シメジ)ではほとんど認められな力つた。下記の表に榭状細胞上の CD54 抗原と CD86抗原の発現変化量を示す (Flowjoソフトによる解析; TreeStar社製)。 [0032] Spider cells stimulated with mushroom hot water extract were collected in a plastic tube, centrifuged and washed with RPMI1640 medium, FITC-labeled anti-human CD45 antibody, PE-labeled anti-human CD86 antibody (both manufactured by eBioscience) 5 μl of each was added, reacted at 4 ° C. for 1 hour, and analyzed for changes in the expression of cell surface antigens using FACS (BD). CD54 and CD86 in rod cells are molecules indispensable for eliciting an immune response, and it is known that an increase in antigen expression indicates the activity state of rod cells. As a result, as shown in FIG. 3, an increase in the expression of CD86 antigen (shift to the right side of the histogram) was confirmed in the rod-shaped cells to which the hot water extract of paddy rice was added as compared to the cells without addition. This expression enhancement is also due to other mushroom extracts. (Maitake, shimeji) was almost unrecognizable. The following table shows changes in expression of CD54 and CD86 antigens on rod cells (analysis with Flowjo software; manufactured by TreeStar).
[0033] [表 2] [0033] [Table 2]
Figure imgf000010_0001
たもぎ茸熱水抽出液を添加することにより榭状細胞の CD54、 CD86抗原の発現が 増加して ヽることが確認され、この効果は他のキノコよりも有意に高 ヽものであった。 実施例 5
Figure imgf000010_0001
It was confirmed that the expression of CD54 and CD86 antigens in the rod cells was increased by adding the hot water extract of the rice ball, and this effect was significantly higher than that of other mushrooms. Example 5
[0034] 撒状細胞からの IL 12産牛.  [0034] IL 12 cows from rod cells.
実施例 1で製造した各種キノコ熱水抽出物を用いて、ヒト榭状細胞力もの IL— 12産 生の増強効果を調べた。インターロイキン 12 (IL— 12)は、主として榭状細胞力 産 生されるサイト力インの 1種であり、 NK細胞、 Thl細胞の活性ィ匕に最も重要な因子で あることが知られている。活性ィ匕榭状細胞力も産生されるインターロイキン 12 (IL—1 2)の産生増強効果は以下の方法にて解析した。実施例 4と同様に誘導した榭状細 胞を細胞濃度を最終的に 2xl05個 Zmlに RPMI1640培地で調整し、 0. 5mlずつ 2 4穴プレートに添加した。成熟化刺激としては、アデノウイルスによる CD40リガンド遺 伝子導入 (AxCACD40L— FZRGD、 300粒子 Z細胞)を行い、さらに各種キノコ 熱水抽出物 (たもぎ茸、マイタケ、シメジ、シィタケ)をそれぞれ最終濃度 2%で添加し 37°Cで 48時間培養した。 The various mushroom hot water extracts produced in Example 1 were used to examine the effect of enhancing IL-12 production from human rod-like cells. Interleukin 12 (IL-12) is a type of cytodynamic force produced mainly by rod-like cell force, and is known to be the most important factor for the activity of NK cells and Thl cells. . The production enhancement effect of interleukin 12 (IL-12), which also produces active rod-like cell force, was analyzed by the following method. The cell concentration of the rod-shaped cells induced in the same manner as in Example 4 was finally adjusted to 2xl0 5 Zml with RPMI1640 medium, and 0.5 ml was added to each 24 well plate. For maturation stimulation, CD40 ligand gene transfer by adenovirus (AxCACD40L—FZRGD, 300 particle Z cells) was performed, and various mushroom hot water extracts (Tamogi mushrooms, mitake mushrooms, shimeji mushrooms) It was added at 2% and cultured at 37 ° C for 48 hours.
[0035] キノコ熱水抽出液で 48時間活性ィ匕刺激した榭状細胞の培養液をプラスチックチュ ーブに回収し、 10000rpm、 5分間遠心して上清を回収した。培養上清を PBSにて 1 0倍に希釈後、 IL— 12含有量を ELISAキット (R&D社製)を用いて測定した。その 結果、キノコ熱水抽出液を添カ卩していない榭状細胞では 13. 0±0. IngZmlの産 生に対して、たもぎ茸熱水抽出液添加榭状細胞では 14. 4±0. IngZmlと有意な 差をもって IL - 12の産生が亢進して 、た。またこの効果は他のキノコ(シィタケ:13. 8±0. IngZmUりも高いものであった。 [0035] The culture solution of rod-shaped cells stimulated with mushroom hot water extract for 48 hours was collected in a plastic tube, and centrifuged at 10,000 rpm for 5 minutes to collect the supernatant. The culture supernatant was diluted 10-fold with PBS, and then the IL-12 content was measured using an ELISA kit (R & D). As a result, 13.0 ± 0. For IngZml production in rod cells not supplemented with mushroom hot water extract, whereas 14.4 ± 0 IL-12 production was enhanced with a significant difference from IngZml. This effect is also effective for other mushrooms (Shitatake: 13. 8 ± 0. IngZmU was also high.
実施例 6  Example 6
[0036] 脾細朐中の抑制件 T細胞の解析  [0036] Suppression of splenic fistula Analysis of T cells
実験動物は S1 ICR系の SPF雄性マウス(日本エスエルシー株式会社)より購入し た生後 5週齢の動物を飼育室で 1週間飼育を行った後に実験を開始した。飼育室の 平均温度は 22°C、湿度 50%の空調施設にて、無菌ケージ内で固形飼料を自由摂 取で飼育した。 ICRマウスの大腿部皮下に実施例 3で示した Sarcomal80細胞を 1匹あ たり 500万個の細胞数を lml注射筒と注射針 26G (テルモ)を用いて投与した。  Experimental animals were 5 weeks old animals purchased from S1 ICR SPF male mice (Japan SLC Co., Ltd.). The breeding room was maintained at an average temperature of 22 ° C and humidity of 50%. Five million cells of Sarcomal80 cells shown in Example 3 were administered subcutaneously to the thigh of ICR mice using an lml syringe and 26G (Terumo).
[0037] 移植同日に実施例 1で製造した被験物質たもぎ茸抽出物をマウス用金属ゾンデに て胃内に強制的に 4mlZkgを連日 21日目まで投与した。対照群として生理食塩水( 大塚製薬 (株))を等量投与した。 1群あたりマウスは 7匹使用した。移植後より週 2回 継続的に腫瘍系を測定し、 21日後まで腫瘍体積を測定したところ、たもぎ茸熱水抽 出物投与群で有為な腫瘍増殖抑制効果が認められた。この結果は実施例 3で示し た増殖抑制と同様であり、抗腫瘍効果が再確認された。  [0037] On the same day of transplantation, the test substance tofu-mushroom extract prepared in Example 1 was forcibly administered into the stomach with a metal sonde for mice up to the 21st day every day. As a control group, an equal amount of physiological saline (Otsuka Pharmaceutical Co., Ltd.) was administered. Seven mice were used per group. The tumor system was measured twice a week after transplantation, and the tumor volume was measured until 21 days later. As a result, a significant tumor growth inhibitory effect was observed in the group treated with hot water extract. This result was the same as the growth suppression shown in Example 3, and the antitumor effect was reconfirmed.
[0038] 腫瘍移植後 22日目に全ての腫瘍移植マウスを深麻酔下にて安楽死後、脾臓を腹 腔内から摘出した。摘出脾臓を培養液の満たされたシャーレ内でほぐしてリンパ球を 主体とした脾細胞液を得た。得られた脾臓細胞中の赤血球を溶血後、細胞数を測定 しプラスチックチューブに 10万個の細胞を入れた。 [0038] On day 22 after tumor transplantation, all tumor-transplanted mice were euthanized under deep anesthesia, and the spleen was removed from the abdominal cavity. The isolated spleen was loosened in a petri dish filled with a culture solution to obtain a spleen cell solution mainly composed of lymphocytes. After red blood cells in the obtained spleen cells were hemolyzed, the number of cells was measured, and 100,000 cells were placed in a plastic tube.
[0039] 脾臓は腫瘍系が大きいほど巨大化しており、繊維芽質でやや赤みが薄ぐ骨髄系 の細胞の混入も多く認められた。たもぎ茸熱水抽出物投与マウスでは生理食塩水投 与マウスに比べて脾臓の巨大化、繊維芽質の程度も軽度であった。 [0039] The larger the tumor system, the larger the spleen, and the myelinous cells, which are fibroblasts and slightly reddish, were often mixed. Mice treated with the hot water extract of Tamogi had a larger spleen and mild fibroblasts than mice given saline.
[0040] 脾細胞中の抑制性 T細胞の蛍光染色は以下に示すとおりに行った。各投与群 7匹 で実施したが、抑制性 T細胞の解析はうち 6匹を用いて施行した。各マウスの実験番 号は以下の通りである。 [0040] Fluorescent staining of inhibitory T cells in spleen cells was performed as follows. Although 7 mice in each treatment group were analyzed, inhibitory T cells were analyzed using 6 of them. The experiment number of each mouse is as follows.
グループ 1:生理食塩水投与群  Group 1: Saline group
151、 152、 153、 154、 155、 157  151, 152, 153, 154, 155, 157
グループ 2:タモギタケ熱水抽出液投与群  Group 2: Tamogitake hot water extract administration group
251、 252、 254, 255、 256、 257 [0041] 各細胞入りのプラスチックチューブに FITC-CD4 (RM4-5; 0.5 μ 1/reaction, eBiosci ence), Biotin-uITR (DTA— 1; 0.5 μ 1/reaction, eBioscienceノ, Avidine— PE (0.2 μ 1/rea ction, BDpharmingen)を添カ卩し、 4°Cで 1時間反応させた。 PBSで細胞を洗浄後 PI染 色にて死細胞を除去し、 FACScalibur (BDバイオサイエンス社製)を用いて蛍光標識 細胞を測定した。抑制性 T細胞数の解析は Flowjoソフトウェア(トリースター社製)を 用いて解析した。 251, 252, 254, 255, 256, 257 [0041] FITC-CD4 (RM4-5; 0.5 μ 1 / reaction, eBioscience), Biotin-uITR (DTA— 1; 0.5 μ 1 / reaction, eBioscience, Avidine— PE (0.2 μ 1 / rea ction, BDpharmingen) and allowed to react for 1 hour at 4 ° C After washing cells with PBS, dead cells were removed with PI staining, and FACScalibur (BD Biosciences) was used. The number of inhibitory T cells was analyzed using Flowjo software (Trister).
[0042] 抑制性 T細胞は CD4陽性 T細胞 (FITC陽性細胞)中の GITR陽性細胞を割合で算 出した。その結果を図 5および 6に示す。 GITR陽性抑制性 T細胞は、たもぎ茸熱水抽 出物投与担癌マウス群(13.2%±3.1%)では生理食塩水投与担癌マウス (33.4%± 10.6 %)にくらべて有為に減少していることが判明した。  [0042] Inhibitory T cells were calculated from the percentage of GITR positive cells in CD4 positive T cells (FITC positive cells). The results are shown in Figs. GITR-positive suppressor T cells were significantly reduced in the tumor-bearing mice group (13.2% ± 3.1%) treated with the extract of hot water extract compared to the tumor-bearing mice treated with saline (33.4% ± 10.6%) Turned out to be.
[0043] 以上の結果から、たもぎ茸熱水抽出物には、担癌状態により誘導される免疫抑制 性 T細胞の出現を阻害できる活性物質が含まれることが示された。このことは、たもぎ 茸抽出物が免疫賦活剤として有用であることを示す。  [0043] From the above results, it was shown that the hot water extract of scallops contains an active substance that can inhibit the appearance of immunosuppressive T cells induced by the cancer-bearing state. This indicates that the bamboo shoot extract is useful as an immunostimulator.
実施例 7  Example 7
[0044] 肉腈に針する予防的杭腈瘍効 の比較  [0044] Comparison of preventive pile ulcer effect on meat shark
たもぎ茸熱水抽出物および市販のキノコ抽出物の Sarcomal80に対する予防的 抗腫瘍効果を測定した。被検物質としては、実施例 1で製造したたもぎ茸熱水抽出 物(ロット 1および 2)、ァガリタス仙生露ロイヤルおよびメシマ(登録商標)ピュア PL2. 5を使用した。  The prophylactic anti-tumor effect of Sarcomal 80 was measured using the hot water extract of the bamboo shoot and the commercial mushroom extract. As test substances, the hot spring water extract (lots 1 and 2), Agaritas Sengyo-ro Royal and Meshima (registered trademark) Pure PL2.5 produced in Example 1 were used.
[0045] Sarcomal80の凍結細胞 (TKG0173、東北大学加齢医学研究所より入手)を、 3 7°Cの温水で急速解凍し、約 10倍量の生理食塩水を加え、遠心分離(1000回転 Z 分、 5分間)し、上清を除去した。この操作を 4回繰り返した後、ペレットに約 3倍量の 生理食塩水を加えて撹拌し、細胞液とした。細胞液 0. 1ml (約 5 X 106個の細胞)を マウスの腹腔内に移植し、 7日後に頸椎脱臼により犠牲死させた。腹部をエタノール 消毒し、滅菌した注射筒を用いて腹水を回収した。各動物から回収した腹水を混合 し、約 5 X 106個の細胞を試験動物の風径部皮下に移植した。 [0045] Sarcomal80 frozen cells (TKG0173, obtained from Tohoku University Institute of Aging Medicine) are rapidly thawed with 37 ° C warm water, added with approximately 10 volumes of physiological saline, and centrifuged (1000 rpm Z). And 5 minutes) and the supernatant was removed. After repeating this operation four times, about 3 times the amount of physiological saline was added to the pellet and stirred to obtain a cell solution. 0.1 ml of cell solution (about 5 × 10 6 cells) was transplanted into the abdominal cavity of mice and sacrificed by cervical dislocation 7 days later. The abdomen was disinfected with ethanol, and ascites was collected using a sterile syringe. Ascites fluid collected from each animal was mixed, and about 5 × 10 6 cells were transplanted subcutaneously into the wind diameter portion of the test animal.
[0046] 試験動物としては 6週齢の雌マウス(Sic : ICR)を各群 10匹ずつ用い、飼料および 水を自由に摂取させた。腫瘍移植前 10日間および移植後 35日間、 1日 1回試験溶 液を経口投与した。投与は、所定量のたもぎ茸熱水抽出物または対照キノコ抽出物 と精製水力もなる試験溶液 12mlZkgをマウス用金属ゾンデを用いて移植動物の胃 内に強制的に投与することにより行った。投与量は以下の表に示すとおりである。 [0046] As test animals, 6-week-old female mice (Sic: ICR) were used, 10 in each group, and food and water were freely fed. Test solution once a day for 10 days before tumor transplantation and 35 days after transplantation The solution was administered orally. The administration was carried out by forcibly administering a predetermined amount of hot water extract of hot spring or control mushroom extract and 12 ml Zkg of test solution having purified hydropower into the stomach of transplanted animals using a metal sonde for mice. The dosage is as shown in the table below.
[0047] [表 3] [0047] [Table 3]
Figure imgf000013_0001
Figure imgf000013_0001
[0048] 腫瘍体積は、実験開始日、移植後 5、 7、 10、 14、 17、 21、 24、 28、 32および 36 日目(観察終了日)に、生存している個体について測定した。腫瘍体積は、ノギスを 用いて腫瘍の短径 (a)および長径 (b)を測定し、以下の式により算出した。 [0048] Tumor volume was measured on surviving individuals on the day of the experiment, on days 5, 7, 10, 14, 17, 21, 24, 28, 32 and 36 (end of observation) after transplantation. The tumor volume was calculated by the following formula after measuring the short axis (a) and long axis (b) of the tumor using calipers.
腫瘍体積 (cm3) =4/3 π a¾/2 Tumor volume (cm 3 ) = 4/3 π a¾ / 2
[0049] 腫瘍重量は、死亡例は発見後速やかに、生存例は最終投与 (移植後 35日目)の 翌日に測定した。試験動物をエーテル麻酔下で放血により安楽死させ、左鼠径部の 腫瘍を摘出し、その重量を測定した。各試験群の腫瘍重量の平均値より、それぞれ の腫瘍増殖阻止率を以下の式により算出した。 [0049] Tumor weight was measured immediately after discovery in the case of death, and the day after the final administration (day 35 after transplantation) in the case of survival. The test animals were euthanized by exsanguination under ether anesthesia, and the tumor in the left inguinal region was excised and weighed. Based on the average value of the tumor weight of each test group, each tumor growth inhibition rate was calculated by the following formula.
腫瘍増殖阻止率 (%)= (1—投与群の平均腫瘍重量 Z対照群の平均腫瘍重量) X 10 0  Tumor growth inhibition rate (%) = (1—average tumor weight in the treated group Z average tumor weight in the control group) X 10 0
[0050] 延命率は、腫瘍移植後の試験動物の生存日数を調べ、以下の式により算出した。  [0050] The survival rate was calculated by the following formula after examining the survival days of the test animals after tumor transplantation.
延命率 (%) = (投与群の平均生存日数 Z対照群の平均生存日数 1) X 100  Survival rate (%) = (mean survival time in treated group Z mean survival time in control group 1) X 100
[0051] 各パラメータについて一元配置分散分析を実施し (有意水準 10%)、群間に有意 差がみられた場合は、平均値にっレ、て Dunnettの多重比較検定を実施した (有意水 準 5%および 1%)。  [0051] A one-way analysis of variance was performed for each parameter (significance level 10%), and if there was a significant difference between groups, Dunnett's multiple comparison test was performed using the mean value (significant water). Associate 5% and 1%).
[0052] 結果を図 7— 9に示す。たもぎ茸熱水抽出物投与群では、腫瘍体積の平均値は経 日的に増力!]したが対照群より低値で推移し、移植後 5日目以降では、対照群と比較 して統計学的に有意に低い値を示した。腫瘍重量の平均値は対照群と比べて 23. 4 - 29. 3%の腫瘍増殖抑制が認められたが、統計学的有意差はみられな力 た。延 命率は 15. 5- 21. 0%であった。また、生存日数において対照群と比べ統計学的 に有意な延命効果がみられた。 [0052] The results are shown in Figures 7-9. In the Tamogi hot water extract administration group, the mean value of the tumor volume Although it increased daily, it remained at a lower value than the control group, and after the fifth day after transplantation, it was statistically significantly lower than the control group. The mean tumor weight was 23.4-29.3% of tumor growth suppression compared to the control group, but there was no statistically significant difference. The survival rate was 15. 5 to 21.0%. In addition, the survival time was statistically significant compared to the control group.
[0053] ァガリタス投与群では、腫瘍体積の平均値は経日的に増力!]したが対照群より低値 で推移し、移植後 5日目以降断続的に、対照群と比較して統計学的に有意に低い値 を示した。腫瘍重量の平均値は対照群と比べて 5. 7%の腫瘍増殖抑制が認められ た力 統計学的有意差はみられなかった。延命率は 20. 6%であった。また、生存日 数において対照群と比べ統計学的に有意な延命効果がみられた。メシマ (登録商標 )投与群では、腫瘍体積の平均値は経日的に増加したが対照群より低値で推移し、 移植後 5日目以降断続的に、対照群と比較して統計学的に有意に低い値を示した。 腫瘍重量の平均値は対照群と比べて 24. 6%の腫瘍増殖抑制が認められた力 統 計学的有意差はみられなかった。延命率は 8. 9%であった。また、生存日数は対照 群と比べ統計学的有意差はみられなかった。  [0053] In the agaritas-administered group, the mean value of the tumor volume increased daily, but remained at a lower value than in the control group, and was statistically different from the control group intermittently after the fifth day after transplantation. The value was significantly lower. The mean value of tumor weight was 5.7% of tumor growth inhibition compared to the control group, and no statistically significant difference was observed. The survival rate was 20.6%. In addition, the survival time was statistically significant compared to the control group. In the Mesima (registered trademark) administration group, the mean value of the tumor volume increased daily, but remained at a lower value than the control group, and statistically compared to the control group intermittently after the fifth day after transplantation. The value was significantly lower. The mean tumor weight was 24.6% less tumor growth than the control group, and no statistically significant difference was observed. The survival rate was 8.9%. There was no statistically significant difference in the days of survival compared with the control group.
[0054] 以上のことから、たもぎ茸熱水抽出物を予防的に投与することにより、腫瘍増殖抑 制効果および延命効果が認められた。  [0054] From the above, it was confirmed that the prophylactic administration of the extract of hot water of potatoes suppresses tumor growth and prolongs life.
産業上の利用可能性  Industrial applicability
[0055] 本発明の抗腫瘍性免疫賦活剤は腫瘍細胞の増殖の抑制に有用である。 [0055] The antitumor immunostimulatory agent of the present invention is useful for suppressing the growth of tumor cells.

Claims

請求の範囲 The scope of the claims
[1] たもぎ茸抽出物を有効成分とする抗腫瘍性免疫賦活剤。  [1] An antitumor immunostimulant comprising a potato paste extract as an active ingredient.
[2] たもぎ茸抽出物を有効成分とする腫瘍細胞増殖抑制剤。  [2] An agent for inhibiting tumor cell growth comprising an extract of Tamogi mushroom as an active ingredient.
[3] たもぎ茸抽出物を有効成分とする免疫賦活性サイト力インの産生増強剤。  [3] An agent for enhancing production of immunostimulatory site force-in, comprising tarogi extract as an active ingredient.
[4] たもぎ茸抽出物を有効成分とする免疫抑制性 T細胞増加の抑制剤。  [4] An inhibitor of immunosuppressive T cell increase, comprising tamago mushroom extract as an active ingredient.
[5] たもぎ茸抽出物からなる免疫賦活用健康食品。  [5] An immune-stimulated health food consisting of a bamboo shoot extract.
[6] たもぎ茸抽出物からなる腫瘍細胞増殖抑制用健康食品。  [6] A health food for suppressing tumor cell growth comprising an extract of Tamogi mushroom.
[7] たもぎ茸抽出物を被験者に投与することにより、被験者において抗腫瘍性免疫を賦 活させる方法。  [7] A method of stimulating antitumor immunity in a subject by administering the sesame extract to the subject.
[8] たもぎ茸抽出物を被験者に投与することにより、被験者において腫瘍細胞の増殖を 抑制する方法。  [8] A method of suppressing tumor cell growth in a subject by administering the tamago mushroom extract to the subject.
[9] たもぎ茸抽出物を被験者に投与することにより、免疫賦活性サイト力インの産生を増 強する方法。  [9] A method for enhancing the production of immunostimulatory site force-in by administering to a subject a Tamogi mushroom extract.
[10] たもぎ茸抽出物を被験者に投与することにより、免疫抑制性 T細胞増加を抑制する 方法。  [10] A method for suppressing an increase in immunosuppressive T cells by administering to a subject a Tamogi mushroom extract.
PCT/JP2005/018004 2004-10-01 2005-09-29 Antitumor immunostimulant containing extract from pleurotus cornucopiae as active ingredient WO2006038527A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006539248A JPWO2006038527A1 (en) 2004-10-01 2005-09-29 Anti-tumor immunostimulant containing tamogi mushroom extract as active ingredient

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004-290528 2004-10-01
JP2004290528 2004-10-01

Publications (1)

Publication Number Publication Date
WO2006038527A1 true WO2006038527A1 (en) 2006-04-13

Family

ID=36142603

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/018004 WO2006038527A1 (en) 2004-10-01 2005-09-29 Antitumor immunostimulant containing extract from pleurotus cornucopiae as active ingredient

Country Status (2)

Country Link
JP (1) JPWO2006038527A1 (en)
WO (1) WO2006038527A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4831711B1 (en) * 2010-09-11 2011-12-07 株式会社スリービー Anti-Candida fungi and prophylactic and / or therapeutic agents for candidiasis comprising Tamogitake extract as an active ingredient
JP6121597B1 (en) * 2016-06-09 2017-04-26 株式会社スリービー Immune response activated cytokine production promoter and Th17 cell differentiation promoter
WO2022230493A1 (en) * 2021-04-26 2022-11-03 サントリーホールディングス株式会社 Composition for increasing leukocytes and/or basophils

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11189542A (en) * 1993-09-02 1999-07-13 Yukiguni Maitake Co Ltd Reduction inhibitor or increasing agent for number of helper t cell in aids
JPH11315096A (en) * 1997-08-08 1999-11-16 New Food Creation Gijutsu Kenkyu Kumiai Antitumoral protein derived from pleurotus cornucopiae and its gene
WO2003030938A1 (en) * 2001-10-09 2003-04-17 Orient Cancer Therary Co.,Ltd. Immunotherapeutics for cancer
JP2004020487A (en) * 2002-06-19 2004-01-22 Orient Cancer Therary:Kk Method of inspecting cancer
JP2005068114A (en) * 2003-08-27 2005-03-17 Api Co Ltd Pleurotus cornucopiae fruit body composition, method for producing the same, and immunopotentiator, anticancer agent and food product

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11189542A (en) * 1993-09-02 1999-07-13 Yukiguni Maitake Co Ltd Reduction inhibitor or increasing agent for number of helper t cell in aids
JPH11315096A (en) * 1997-08-08 1999-11-16 New Food Creation Gijutsu Kenkyu Kumiai Antitumoral protein derived from pleurotus cornucopiae and its gene
WO2003030938A1 (en) * 2001-10-09 2003-04-17 Orient Cancer Therary Co.,Ltd. Immunotherapeutics for cancer
JP2004020487A (en) * 2002-06-19 2004-01-22 Orient Cancer Therary:Kk Method of inspecting cancer
JP2005068114A (en) * 2003-08-27 2005-03-17 Api Co Ltd Pleurotus cornucopiae fruit body composition, method for producing the same, and immunopotentiator, anticancer agent and food product

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KAMEYAMA N. ET AL: "Kinokorui ni yoru IFN-gamma Narabini IL-4 ni Kansuru Yudono.", JAPANESE SOCIETY OF VETERINARY SCIENCE GAKUJUTSU SHUNKAI KOEN YOSHISHU., vol. 138, 1 August 2004 (2004-08-01), pages 82, XP002998452 *
MATSUMOTO T. ET AL: "Tamogitake no Seibun Kenkyu.", THE JAPANESE SOCIETY OF PHARMACOGNOSY NENKAI KOEN YOSHISHU., vol. 51, 9 August 2004 (2004-08-09), pages 95, XP002998451 *
MISAKI A. ET AL: "Kishimejika Shokuyo Kinoko (Hiratake, Tamogitake) no Tato no Kagakuteki Seishitsu Oyobi Koshuyo Sayo.", ANNUAL REPORT OF HUMAN LIFE SCIENCE., vol. 39, 1991, pages 1 - 8, XP002998450 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4831711B1 (en) * 2010-09-11 2011-12-07 株式会社スリービー Anti-Candida fungi and prophylactic and / or therapeutic agents for candidiasis comprising Tamogitake extract as an active ingredient
JP6121597B1 (en) * 2016-06-09 2017-04-26 株式会社スリービー Immune response activated cytokine production promoter and Th17 cell differentiation promoter
JP2017218431A (en) * 2016-06-09 2017-12-14 株式会社スリービー Immune response-activating cytokine production promoter and th17 cell differentiation promoter
WO2022230493A1 (en) * 2021-04-26 2022-11-03 サントリーホールディングス株式会社 Composition for increasing leukocytes and/or basophils

Also Published As

Publication number Publication date
JPWO2006038527A1 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
Cao et al. Ganoderma: A cancer immunotherapy review
Tang et al. Golden needle mushroom: a culinary medicine with evidenced-based biological activities and health promoting properties
Shrestha et al. The immunostimulating role of lichen polysaccharides: a review
Shahbazi et al. Immunostimulants: types and functions
WO2015156339A1 (en) Immune balance adjustment agent
Biedron et al. Agaricus blazei Murill-immunomodulatory properties and health benefits
Yang et al. Optimization of the fermentation process of Cordyceps sobolifera Se-CEPS and its anti-tumor activity in vivo
JP3621404B1 (en) Immunity enhancing active agent
US20190070237A1 (en) Traditional chinese medicine composition and use thereof
Jain et al. Immunostimulants: concepts, types and functions
Song et al. A hydroxyethyl derivative of chrysin exhibits anti-inflammatory activity in dendritic cells and protective effects against dextran sodium salt-induced colitis in mice
KR101916271B1 (en) Composition for Enhancing Immunity, Functional Food and Pharmaceutical Composition
WO2006038527A1 (en) Antitumor immunostimulant containing extract from pleurotus cornucopiae as active ingredient
KR20130117491A (en) Composition for preventing and treating inflammatory or immune diseases comprising plocamium telfairiae extract
JP2004344079A (en) Chaaga-containing health auxiliary food
US10967016B2 (en) Traditional Chinese medicine composition and use thereof
Choi et al. Immunomodulatory effects of ethanol extract of germinated ice plant (Mesembryanthemum crystallinum)
KR101640284B1 (en) Composition for preventing or treating immune disease comprising metformin and quercetin as active ingredients
KR101429379B1 (en) Use of Composition for Dendritic Cell Activation Comprising Pueraria lobata Polysaccharide
RU2307157C2 (en) Basidiomycetes, extract therefrom, dietary products, immunostimulators and edible basidiomycetes
CN105412155B (en) Trichoderma pseudokoningii exocellular polysaccharide treats and prevents the application of colon cancer and its is combined the application of chemotherapeutic drug therapy colon cancer
Sakaguchi et al. Augmentation of cytolytic activity in murine natural killer cells and inhibition of tumor growth by the ethanol fraction of oyster extract
Yap et al. The medicinal benefits of lentinan (β-1, 3-D glucan) from Lentinus edodes (Berk.) Singer (shiitake mushroom) through oral administration
Pohorska et al. Reconstruction of NK cells during complex cancer treatment
Shih et al. The stimulating effects of polyphenol and protein fractions from jelly fig (Ficus awkeotsang Makino) achenes against proliferation of leukemia cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006539248

Country of ref document: JP

122 Ep: pct application non-entry in european phase

Ref document number: 05788186

Country of ref document: EP

Kind code of ref document: A1